Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8GJ1E
|
|||
| Drug Name |
JNJ-64281802
|
|||
| Synonyms |
JNJ-1802
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Dengue [ICD-11: 1D20-1D2Z; ICD-10: A90, R50] | Phase 2 | [1] | |
| Company |
JOHNSON & JOHNSON
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 2 (mGluR2) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glutamatergic synapse | ||||
| Cocaine addiction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group II pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04480736) A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants. U.S.National Institutes of Health. | |||
| REF 2 | Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. J Psychopharmacol. 2015 Apr;29(4):414-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.